AYTU BioPharma
AYTU
33 hedge funds and large institutions have $3.05M invested in AYTU BioPharma in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
2,500% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 1
313% more funds holding
Funds holding: 8 → 33 (+25)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.19% less ownership
Funds ownership: 0.2% → 0.01% (-0.19%)
63% less capital invested
Capital invested by funds: $8.23M → $3.05M (-$5.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$460K |
| 2 |
Renaissance Technologies
New York
|
+$295K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$237K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$135K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$77.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$7.73M |
| 2 |
SC
Searle & Co
Greenwich,
Connecticut
|
-$112K |
| 3 |
Morgan Stanley
New York
|
-$36.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
26
IFP Advisors
Tampa,
Florida
| $5K | +$2.9K | +15 | New |
|
|
27
Morgan Stanley
New York
| $3K | -$36.7K | -190 | -95% |
|
|
AF
28
Advisornet Financial
Minnetonka,
Minnesota
| $2K | +$965 | +5 | New |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$386 | +2 | New |
|
|
EWM
30
Endurance Wealth Management
Providence,
Rhode Island
| $1K | +$579 | +3 | New |
|
|
AC
31
Armistice Capital
New York
| – | -$7.73M | -39,750 | Closed |
|
|
TWA
32
TCI Wealth Advisors
Tucson,
Arizona
| – | +$193 | +1 | New |
|
33
Wells Fargo
San Francisco,
California
| – | +$193 | +1 | New |
|
|
RCA
34
Ranch Capital Advisors
Sarasota,
Florida
| – | +$386 | +2 | New |
|
AYTU Hedge Fund Activity: Q1 2020 in Review
33 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2020, worth a combined $3.05M — down 63% from $8.23M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AYTU positions and 1 closed out — a net gain of 25 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $460K. The largest seller was Armistice Capital, exiting entirely with an estimated $7.73M sold.
- 33 institutional investors held AYTU BioPharma (AYTU) as of Q1 2020, up from 8 in Q4 2019.
- Funds reported $3.05M of AYTU BioPharma stock for Q1 2020, down 63% quarter-over-quarter.
- 26 funds opened new AYTU BioPharma positions in Q1 2020 and 1 closed out, a net change of +25 holders.
- The largest AYTU BioPharma buyer in Q1 2020 was Vanguard Group, an estimated $460K added.
- The largest AYTU BioPharma seller in Q1 2020 was Armistice Capital, an estimated $7.73M sold.
Based on aggregated 13F filings for Q1 2020.